Agenebio Inc

AgeneBio, Inc. is a Baltimore-based biopharmaceutical company dedicated to discovering and developing innovative therapeutics for individuals at risk of neurological and psychiatric conditions. With a mission to improve the lives of patients, their families, and society as a whole, AgeneBio focuses on the prevention of Alzheimer's dementia through their lead late-stage clinical program.

Driven by a commitment to scientific advancement, AgeneBio also explores novel programs such as the GABA A 5 Discovery Program, aiming to address conditions like autism and schizophrenia. With a strong emphasis on research and development, AgeneBio strives to bring forth groundbreaking solutions for patients at risk of these debilitating diseases.

Generated from the website